Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing Treatment with CC-122 for Participants from Prior CC-122 Trials
NCT05688475Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of avadomide in non-Hodgkin lymphoma (NHL), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with serious adverse events and Number of deaths. Started Apr 2023; status: active, not recruiting.
02
Drugs
avadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05688475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688475.